New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children’s Hospital of Philadelphia, presented on this topic at the 2024 American Society of Hematology Annual Meeting.